Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
Become a Member | Sign in
Home>News>This Article

NSF Funds Research Partnership Between Bioo Scientific and Mirna Therapeutics

Published: Thursday, July 22, 2010
Last Updated: Thursday, July 22, 2010
Bookmark and Share
The funding will support tumor regression and pharmacokinetic studies on targeted delivery of microRNAs.

Bioo Scientific Corporation announced today that it has been awarded an additional $100,000 for its Small Business Innovation Research (SBIR) Phase II grant from the National Science Foundation.

The funding will support tumor regression and pharmacokinetic studies featuring escalating doses of a microRNA-based therapeutic candidate from Mirna Therapeutics, Inc., used in combination with Bioo Scientific’s targeted transport technology. The supplemental funding brings the total financial support for this phase of the NSF project to $600,000.

The targeted transport technology (T3) combines a positively charged carrier compound and an antibody that is specific to a cell surface receptor to directly deliver RNA-interfering (RNAi) mediator payloads to specific cells in the body. The carrier-antibody conjugate, loaded with an RNAi mediator, can be administered systemically or locally to an animal (or cultured cells) where it is internalized by cells bearing surface receptors that are targeted by the antibody. Upon cell entry, the RNAi mediator is released from the T3 delivery vehicle and allowed to silence the expression of its intended targets. Bioo Scientific has been expanding its collection of antibody carrier controls and recently launched a conjugation kit to enable customers to develop antibody delivery vehicles in their own laboratories.

The RNAi mediator provided by Mirna Therapeutics is a mimic of the potent tumor suppressor microRNA, miR-34, which has proven to be effective and safe when used in animal models of cancer. miR-34 is a key component of the p53 tumor suppressor pathway and is responsible for regulating multiple cancer-related genes and cellular processes.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Custom RNA Interference Service
BIOO Scientific is launching a service to perform in vivo RNAi testing to facilitate progress in the drug pipeline.
Thursday, April 12, 2007
Scientific News
NIH Supports New Studies to Find Alzheimer’s Biomarkers in Down Syndrome
Initiative will track dementia onset, progress in Down syndrome volunteers.
New Gene Map Reveals Cancer’s Achilles’ Heel
Team of researchers switches off almost 18,000 genes
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
New Way to Force Stem Cells to Become Bone Cells
Potential therapies based on this discovery could help people heal bone injuries or set hardware, such as replacement knees and hips.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos